Molecular characterization of CYP2B6 substrates

被引:39
|
作者
Ekins, Sean [1 ,2 ,3 ]
Iyer, Manisha [4 ]
Krasowski, Matthew D. [4 ]
Kharasch, Evan D. [5 ]
机构
[1] Collaborat Chem, Jenkintown, PA 19046 USA
[2] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[4] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA
[5] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO 63110 USA
关键词
ChemSpider; CYP2B6; descriptors; properties; QSAR;
D O I
10.2174/138920008784746346
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CYP2B6 has not been as fully characterized at the molecular level as other members of the human cytochrome P450 family. As more widely used in vitro probes for characterizing the involvement of this enzyme in the metabolism of xenobiotics have become available, the number of molecules identified as CYP2B6 substrates has increased. In this study we have analyzed the available kinetic data generated by multiple laboratories with human recombinant expressed CYP2B6 and along with calculated molecular properties derived from the ChemSpider database, we have determined the molecular features that appear to be important for CYP2B6 substrates. In addition we have applied 2D and 3D QSAR methods to generate predictive pharmacophore and 2D models. For 28 molecules with Km data, the molecular weight (mean +/- SD) is 253.78 +/- 74.03, ACD/logP is 2.68 +/- 1.51, LogD(pH5.5) is 1.51 +/- 1.43, LogD(pH7.4) is 2.02 +/- 1.25, hydrogen bond donor (HBD) count is 0.57 +/- 0.57, hydrogen bond acceptor (HBA) count is 2.57 +/- 1.37, rotatable bonds is 3.50 +/- 2.71 and total polar surface area (TPSA) is 27.63 +/- 19.42. A second set of 15 molecules without Km data possessed similar mean molecular property values. These properties are comparable to those of a set of 21 molecules used in a previous pharmacophore modeling study (Ekins et al., J Pharmacol Exp Ther 288 (1), 21-29, 1999). Only the LogD and HBD values were statistically significantly different between these different datasets. We have shown that CYP2B6 substrates are generally small hydrophobic molecules that are frequently central nervous system active, which may be important for drug discovery research.
引用
收藏
页码:363 / 373
页数:11
相关论文
共 50 条
  • [41] The effects of CYP2B6 inactivators on the metabolism of ciprofol
    Lu, Ming
    Zhang, Xiaorui
    Li, Wenli
    Li, Xiangchen
    Li, Shan
    Yin, Xiaoyu
    Zhang, Zhiqing
    PLOS ONE, 2024, 19 (07):
  • [42] Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane
    D'Avolio, Antonio
    De Francia, Silvia
    Basile, Vittoria
    Cusato, Jessica
    De Martino, Francesca
    Pirro, Elisa
    Piccione, Francesca
    Ardito, Arianna
    Zaggia, Barbara
    Volante, Marco
    Di Perri, Giovanni
    Terzolo, Massimo
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (06): : 293 - 300
  • [43] Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele
    Hwang, In Cheol
    Park, Ji Young
    Ahn, Hong Yup
    Kim, Kyoung Kon
    Suh, Heuy Sun
    Ko, Ki Dong
    Kim, Kyoung-Ah
    CLINICA CHIMICA ACTA, 2014, 428 : 77 - 81
  • [44] CYP2B6: Inching towards personalized medicine
    Gogtay, N. J.
    JOURNAL OF POSTGRADUATE MEDICINE, 2012, 58 (04) : 233 - 234
  • [45] Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions
    Mayumi, Kei
    Hanioka, Nobumitsu
    Masuda, Kazufumi
    Koeda, Akiko
    Naito, Shinsaku
    Miyata, Atsuro
    Narimatsu, Shizuo
    BIOCHEMICAL PHARMACOLOGY, 2013, 85 (08) : 1182 - 1194
  • [46] Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure:: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4
    Lewis, DFV
    Lake, BG
    Dickins, M
    Eddershaw, PJ
    Tarbit, MH
    Goldfarb, PS
    XENOBIOTICA, 1999, 29 (04) : 361 - 393
  • [47] Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles
    Gonzalo Restrepo, Juan
    Martinez, Carmen
    Garcia-Agundez, Augusto
    Gaviria, Elmer
    Julio Laguna, Jose
    Garcia-Martin, Elena
    Agundez, Jose A. G.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (12): : 773 - 778
  • [48] The functional role of CYP2B6 in human drug metabolism:: Substrates and inhibitors in vitro, in vivo and in silico
    Turpeinen, Miia
    Raunio, Hannu
    Pelkonen, Olavi
    CURRENT DRUG METABOLISM, 2006, 7 (07) : 705 - 714
  • [49] Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
    Rotger, Margalida
    Saumoy, Maria
    Zhang, Kunlin
    Flepp, Markus
    Sahli, Roland
    Decosterd, Laurent
    Telenti, Amalio
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (10): : 885 - 890
  • [50] Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6
    Lu, H.
    Wang, J. J.
    Chan, K. K.
    Philip, P. A.
    XENOBIOTICA, 2006, 36 (05) : 367 - 385